For the primary time, folks beneath the age of 18 could quickly be eligible for a COVID-19 booster shot within the U.S.
On Tuesday, Pfizer CEO and Chairman Albert Bourla stated the vaccine maker had submitted its request to the U.S. Meals and Drug Administration to increase the emergency use authorization of a booster dose of the Pfizer-BioNTech COVID-19 vaccine to incorporate 16- and 17-year-olds.
Bourla made the announcement on Twitter, saying that “it’s our hope to offer sturdy safety for as many individuals as attainable, significantly in mild of the brand new variant” — a reference to omicron, which has not but been detected within the U.S.
In the mean time, solely folks 18 and older are eligible for a COVID-19 booster shot within the U.S., and it should be a minimum of six months after receiving a second dose of both the Pfizer or Moderna vaccines. Adults 18 and older who acquired the Johnson & Johnson vaccine can get a booster after two months.
In October, Pfizer and BioNTech introduced the outcomes of a randomized research of 10,000 folks 16 years of age and older that confirmed a booster dose “restored vaccine safety in opposition to COVID-19 to the excessive ranges achieved after the second dose,” in accordance with a press launch from the businesses.
Pfizer’s effort to increase eligibility for boosters to some adults beneath 18 comes as high federal well being officers are urging all People who qualify to get a booster shot.